(99m)Tc-radiolabelled peptides for tumour imaging: present and future

Area of Science:

• Nuclear medicine
• Oncology
• Peptide chemistry

Background:

• Receptor-binding peptides are crucial for developing targeted radiopharmaceuticals against tumors.
• Overexpressed receptors on human tumors make peptide ligands valuable for cancer imaging and therapy.
• Solid-phase peptide synthesis and bifunctional chelators enable radiolabeling of bioactive peptides.

Purpose of the Study:

• To highlight the significance of receptor-binding peptides in cancer radiopharmaceutical development.
• To discuss the utility of these peptides for diagnostic imaging and therapeutic applications.
• To emphasize the role of technetium-99m as an ideal radionuclide for diagnostic purposes.

Main Methods:

• Utilizing solid-phase peptide synthesis for peptide preparation.
• Employing bifunctional chelating agents for radiolabeling.
• Leveraging the properties of technetium-99m for diagnostic imaging.

Main Results:

• Development of a wide variety of radiopharmaceutical molecules.
• Demonstration of peptide ligands as attractive agents for cancer diagnosis and therapy.
• Identification of technetium-99m as a suitable radionuclide for diagnostic imaging.

Conclusions:

• Receptor-binding peptides are key in designing tumor-specific radiopharmaceuticals.
• Technetium-99m offers advantageous nuclear properties for cancer diagnostic imaging.
• The combination of peptide synthesis and radiolabeling facilitates the creation of novel radiopharmaceutical agents.